TY - JOUR T1 - Palliative Short-course Radiotherapy in Advanced Pelvic Cancer: A Phase II Study (SHARON Project) JF - Anticancer Research JO - Anticancer Res SP - 4237 LP - 4242 DO - 10.21873/anticanres.13585 VL - 39 IS - 8 AU - ELEONORA FARINA AU - GABRIELLA MACCHIA AU - GIAMBATTISTA SIEPE AU - ALICE ZAMAGNI AU - MILLY BUWENGE AU - ERICA SCIROCCO AU - FRANCESCO CELLINI AU - BINIYAM T. DERESSA AU - WONDEMAGEGNEHU TIGENEH AU - KAMAL A.F.M. UDDIN AU - MOSTAFĂ€ AZIZ SUMON AU - LUCIANA CARAVATTA AU - DOMENICO GENOVESI AU - FLORA ANNA MAURO AU - SILVIA CAMMELLI AU - SAVINO CILLA AU - ALESSIO G. MORGANTI AU - FRANCESCO DEODATO Y1 - 2019/08/01 UR - http://ar.iiarjournals.org/content/39/8/4237.abstract N2 - Aim: To define safety and efficacy of a palliative, short-course accelerated radiation therapy for symptomatic locally advanced primary pelvic cancer. Materials and Methods: A phase II trial was planned based on the minimax Simon's two-stage design. A total of 18 Gy in 4.5 Gy/fraction administered twice a day was delivered (SHARON). Pain and quality of life were recorded according to the Visual Analogue self-assessment and the cancer linear analog scales (CLAS), respectively. Results: Twenty-five patients were enrolled in the study. The most frequent baseline symptoms were pain (48%), bleeding (40%), bleeding/pain (8%), and intestinal sub-occlusion (4%). The overall palliative response rate was 96.0%, with a median palliative duration of 6 months. An improvement of quality-of-life indices (well-being, fatigue, and ability to perform daily activities) was noted in 64.0%, 36.0%, and 48.0% of patients, respectively. Conclusion: The SHARON regimen was well tolerated and effective in the palliative treatment of patients with locally advanced pelvic cancer. Based on these results, a multicentric prospective phase III trial is ongoing to compare this regimen with traditional 2-week radiotherapy treatment. ER -